Invivyd Reports Q4 2025 Financial Results and Provides Business Updates, Including 25% YoY Growth in PEMGARDA Net Product Revenue and Initiation of DECLARATION Phase 3 Pivotal Clinical Trial for VYD2311.

Invivyd reported Q4 2025 net product revenue of $17.2 million, a 25% YoY and 31% QoQ increase. The company raised over $200 million in financing transactions in 2H 2025, resulting in a year-end cash balance of $226.7 million. Invivyd initiated its DECLARATION Phase 3 clinical trial for VYD2311, a vaccine-alternative antibody for COVID prevention, with top-line data expected mid-2026. The trial is on track with full enrollment achieved, and the FDA granted Fast Track designation for VYD2311.